tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
11.480USD
+0.110+0.97%
Close 11/10, 16:00ETQuotes delayed by 15 min
3.61BMarket Cap
611.12P/E TTM

Amneal Pharmaceuticals Inc

11.480
+0.110+0.97%

More Details of Amneal Pharmaceuticals Inc Company

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Amneal Pharmaceuticals Inc Info

Ticker SymbolAMRX
Company nameAmneal Pharmaceuticals Inc
IPO dateNov 18, 2009
CEOMr. Chintu Patel
Number of employees8100
Security typeOrdinary Share
Fiscal year-endNov 18
Address400 Crossing Boulevard, 3rd Floor
CityBRIDGEWATER
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code08807
Phone19089473120
Websitehttps://amneal.com/
Ticker SymbolAMRX
IPO dateNov 18, 2009
CEOMr. Chintu Patel

Company Executives of Amneal Pharmaceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
-55.89%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Kiely
Mr. John J. Kiely
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
-55.89%
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
Other
228.38M
31.52%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
Other
228.38M
31.52%

Shareholding Stats

Updated: Wed, Oct 8
Updated: Wed, Oct 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
Other
55.24%
Shareholders
Shareholders
Proportion
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
Other
55.24%
Shareholder Types
Shareholders
Proportion
Individual Investor
46.44%
Investment Advisor
17.90%
Hedge Fund
12.11%
Investment Advisor/Hedge Fund
11.19%
Private Equity
3.93%
Research Firm
1.17%
Pension Fund
0.35%
Bank and Trust
0.19%
Family Office
0.02%
Other
6.71%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
434
147.18M
46.82%
-21.09M
2025Q2
430
283.67M
90.50%
-32.81M
2025Q1
437
285.44M
91.08%
-30.39M
2024Q4
413
285.94M
92.29%
-32.70M
2024Q3
398
304.85M
98.50%
-8.45M
2024Q2
391
304.30M
98.56%
+52.65M
2024Q1
375
272.60M
88.40%
+17.73M
2023Q4
366
275.21M
90.82%
+129.07M
2023Q3
354
120.75M
78.38%
-3.68M
2023Q2
353
115.91M
75.59%
-7.89M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Patel (Tushar Bhikhubhai)
48.58M
15.47%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.16%
+351.47K
+1.39%
Mar 14, 2025
Patel (Dipan)
23.83M
7.6%
--
--
Mar 14, 2025
Patel (Chirag K)
22.13M
7.05%
--
--
Aug 06, 2025
Akram (Mahesh)
20.56M
6.55%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
17.49M
5.57%
+1.78M
+11.34%
Jun 30, 2025
TPG Capital, L.P.
12.33M
3.93%
--
--
Jun 30, 2025
Rubric Capital Management LP
11.71M
3.73%
+974.36K
+9.08%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.64M
3.39%
-499.58K
-4.49%
Jun 30, 2025
Citadel Advisors LLC
5.62M
1.79%
-1.87M
-24.92%
Jun 30, 2025
View more

Related ETFs

Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.85%
SPDR S&P Pharmaceuticals ETF
1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
0.77%
First Trust NASDAQ Pharmaceuticals ETF
0.69%
iShares U.S. Pharmaceuticals ETF
0.63%
First Trust Small Cap Growth AlphaDEX Fund
0.55%
ProShares Ultra Nasdaq Biotechnology
0.32%
Invesco Nasdaq Biotechnology ETF
0.32%
View more
Invesco Pharmaceuticals ETF
Proportion2.85%
SPDR S&P Pharmaceuticals ETF
Proportion1.72%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.77%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.69%
iShares U.S. Pharmaceuticals ETF
Proportion0.63%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.55%
ProShares Ultra Nasdaq Biotechnology
Proportion0.32%
Invesco Nasdaq Biotechnology ETF
Proportion0.32%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI